ATE442129T1 - Camptothecin-carboxylat-formulierungen - Google Patents
Camptothecin-carboxylat-formulierungenInfo
- Publication number
- ATE442129T1 ATE442129T1 AT03761518T AT03761518T ATE442129T1 AT E442129 T1 ATE442129 T1 AT E442129T1 AT 03761518 T AT03761518 T AT 03761518T AT 03761518 T AT03761518 T AT 03761518T AT E442129 T1 ATE442129 T1 AT E442129T1
- Authority
- AT
- Austria
- Prior art keywords
- carboxylate
- camptothecine
- cationic molecule
- derivative
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1806—Suspensions, emulsions, colloids, dispersions
- A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Radiology & Medical Imaging (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39124602P | 2002-06-26 | 2002-06-26 | |
US39124402P | 2002-06-26 | 2002-06-26 | |
EP02018907A EP1393719A1 (de) | 2002-08-23 | 2002-08-23 | Camptothecin-Carboxylat Formulierungen |
PCT/EP2003/006760 WO2004002454A1 (en) | 2002-06-26 | 2003-06-26 | Camptothecin-carboxylate formulations |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE442129T1 true ATE442129T1 (de) | 2009-09-15 |
Family
ID=31197816
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03761518T ATE442129T1 (de) | 2002-06-26 | 2003-06-26 | Camptothecin-carboxylat-formulierungen |
Country Status (8)
Country | Link |
---|---|
US (1) | US20060128736A1 (de) |
EP (2) | EP1393719A1 (de) |
JP (1) | JP2005535633A (de) |
AT (1) | ATE442129T1 (de) |
AU (1) | AU2003242765B2 (de) |
CA (1) | CA2489555A1 (de) |
DE (1) | DE60329210D1 (de) |
WO (1) | WO2004002454A1 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060222694A1 (en) * | 2003-06-27 | 2006-10-05 | Oh Choon K | Stabilized topotecan liposomal composition and methods |
EP1547580A1 (de) * | 2003-12-23 | 2005-06-29 | MediGene Oncology GmbH | Ladung eines Camptothecin Wirkstoffes in colloidalen Nanopartikeln |
EP1547582A1 (de) * | 2003-12-23 | 2005-06-29 | MediGene Oncology GmbH | Methode zur Herstellung von lipidkomplexiertem Camptothecincarboxylat |
FR2870741B1 (fr) * | 2004-05-25 | 2008-03-14 | Coletica Sa | Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant. |
JP2006056807A (ja) * | 2004-08-18 | 2006-03-02 | Konica Minolta Medical & Graphic Inc | 光線力学療法製剤 |
JP4715133B2 (ja) * | 2004-08-26 | 2011-07-06 | コニカミノルタエムジー株式会社 | 抗腫瘍リポソーム製剤およびその製造方法 |
JP2006069929A (ja) * | 2004-08-31 | 2006-03-16 | Konica Minolta Medical & Graphic Inc | 真菌症治療製剤およびその製造方法 |
GT200500310A (es) | 2004-11-19 | 2006-06-19 | Compuestos organicos | |
SA06270147B1 (ar) | 2005-06-09 | 2009-12-22 | نوفارتيس ايه جي | عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين |
US8877217B2 (en) * | 2005-10-18 | 2014-11-04 | Amorepacific Corporation | Cationic polymer nanoparticles encapsulating an active ingredients, and the cosmetic composition containing the same |
BRPI0716890A2 (pt) * | 2006-09-22 | 2013-10-22 | Labopharm Inc | Composição, e, método de produção de uma composição, de administração de um agente farmaceuticamente ativo insolúvel em água a um mamífero, e de tratamento de câncer em um mamífero |
JP2008094809A (ja) * | 2006-10-16 | 2008-04-24 | Kose Corp | リポソーム組成物およびそれを配合する化粧料、並びに皮膚外用剤 |
WO2008070009A2 (en) * | 2006-12-01 | 2008-06-12 | Alza Corporation | Treating solid tumors and monocytic leukemia using topoisomerase inhibitors in liposomes |
US8067432B2 (en) * | 2008-03-31 | 2011-11-29 | University Of Kentucky Research Foundation | Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors |
EP2113257A1 (de) * | 2008-04-30 | 2009-11-04 | Consorzio per il Centro di Biomedica Moleculare Scrl | Polyelektrolyt mit positiver Überschussladung zur Verwendung als Medikament und Diagnose von Krebs |
JP5835741B2 (ja) | 2010-02-26 | 2015-12-24 | 国立大学法人 長崎大学 | 抗原または薬物送達複合体 |
EP2394640A1 (de) * | 2010-05-21 | 2011-12-14 | MediGene AG | Verbesserte liposomale Formulierungen von lipophilen Verbindungen |
CN102133404B (zh) * | 2011-03-23 | 2013-01-16 | 成都诺恩生物科技有限公司 | 一种肿瘤靶向治疗药物载体、其制备方法及其应用 |
US9675537B2 (en) * | 2014-06-30 | 2017-06-13 | Johnson & Johnson Consumer Inc. | Hair growth composition and method |
WO2021255262A1 (en) | 2020-06-19 | 2021-12-23 | Sylentis Sau | siRNA AND COMPOSITIONS FOR PROPHYLACTIC AND THERAPEUTIC TREATMENT OF VIRUS DISEASES |
EP4015634A1 (de) | 2020-12-15 | 2022-06-22 | Sylentis, S.A.U. | Sirna und zusammensetzungen zur prophylaktischen und therapeutischen behandlung von viruskrankheiten |
CN117482240B (zh) * | 2024-01-03 | 2024-04-26 | 深圳大学总医院 | 一种rna疫苗递送制剂及其制备方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897355A (en) * | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4981968A (en) * | 1987-03-31 | 1991-01-01 | Research Triangle Institute | Synthesis of camptothecin and analogs thereof |
US5180722A (en) * | 1987-04-14 | 1993-01-19 | Research Triangle Institute | 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs |
US5654484A (en) * | 1987-10-08 | 1997-08-05 | Merrell Pharmaceuticals Inc. | Polyamine derivatives as antineoplastic agents |
KR0157428B1 (ko) * | 1989-02-17 | 1998-11-16 | 알렌 불룸 | 비 전달용 지질부형제와 그 사용법 |
US5552156A (en) * | 1992-10-23 | 1996-09-03 | Ohio State University | Liposomal and micellular stabilization of camptothecin drugs |
JPH09504517A (ja) * | 1993-09-27 | 1997-05-06 | スミスクライン・ビーチャム・コーポレイション | カンプトテシン処方物 |
US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5830430A (en) * | 1995-02-21 | 1998-11-03 | Imarx Pharmaceutical Corp. | Cationic lipids and the use thereof |
US5834012A (en) * | 1995-05-03 | 1998-11-10 | Roman Perez-Soler | Lipid complexed topoisomerase I inhibitors |
US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
DK1017675T3 (da) * | 1997-02-14 | 2006-10-16 | Bionumerik Pharmaceuticals Inc | Stærkt lipofile camptothecinderivater |
WO1999013816A2 (en) * | 1997-09-16 | 1999-03-25 | Nexstar Pharmaceuticals, Inc. | Liposomal camptothecin formulations |
ATE238039T1 (de) * | 1998-09-16 | 2003-05-15 | Alza Corp | In liposomen eingeschlossene topoisomerase inhibitoren |
DE10109898A1 (de) * | 2001-02-21 | 2002-09-05 | Novosom Gmbh | Lipide mit veränderlicher Ladung |
-
2002
- 2002-08-23 EP EP02018907A patent/EP1393719A1/de not_active Withdrawn
-
2003
- 2003-06-26 DE DE60329210T patent/DE60329210D1/de not_active Expired - Fee Related
- 2003-06-26 JP JP2004516694A patent/JP2005535633A/ja active Pending
- 2003-06-26 CA CA002489555A patent/CA2489555A1/en not_active Abandoned
- 2003-06-26 AU AU2003242765A patent/AU2003242765B2/en not_active Ceased
- 2003-06-26 US US10/519,193 patent/US20060128736A1/en not_active Abandoned
- 2003-06-26 AT AT03761518T patent/ATE442129T1/de not_active IP Right Cessation
- 2003-06-26 WO PCT/EP2003/006760 patent/WO2004002454A1/en active Application Filing
- 2003-06-26 EP EP03761518A patent/EP1553923B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP1393719A1 (de) | 2004-03-03 |
EP1553923B1 (de) | 2009-09-09 |
JP2005535633A (ja) | 2005-11-24 |
DE60329210D1 (en) | 2009-10-22 |
EP1553923A1 (de) | 2005-07-20 |
US20060128736A1 (en) | 2006-06-15 |
AU2003242765A1 (en) | 2004-01-19 |
WO2004002454A1 (en) | 2004-01-08 |
AU2003242765B2 (en) | 2008-11-06 |
CA2489555A1 (en) | 2004-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE442129T1 (de) | Camptothecin-carboxylat-formulierungen | |
DE60003863D1 (de) | Dioxocyclopentylhydroxamsäure | |
DK1022277T3 (da) | Nye taxanderivater | |
EP2266623A3 (de) | Prodrugs mit neuen biospaltbaren Verbindern | |
IL190643A0 (en) | Novel dihydropseudoerythromycin derivatives | |
FR2678615B1 (fr) | Benzofuranne-2-ones thiomethylees, leur preparation et leur application comme stabilisants de matieres organiques. | |
BRPI0412851A (pt) | benzamidazóis de n-metila-substituìdos | |
EP1709699B8 (de) | Konjugierte polymere, deren darstellung und verwendung | |
ATE295363T1 (de) | Beta-laktame zur herstellung von taxanen mit furyl oder thienyl substituierter seitenkette | |
AR022588A1 (es) | Derivados de mevinolina | |
WO2003026563A3 (en) | Conjugated anti-psychotic drugs and uses thereof | |
DK1197215T3 (da) | Anthelmintiske sammensætninger | |
ECSP044971A (es) | Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson | |
DE69400125T2 (de) | 9-Deoxo-9a-aza-11-deoxy-9a-homoerythromycin A 9a, 11-zyklische Carbamate | |
NO20053997D0 (no) | Oligosaccharidderivat | |
UY27628A1 (es) | "2'-halo -3',5'-dialcoxi-fen-1'il-2-imidazolidinas y su uso como un fármaco" | |
BR0002507A (pt) | Derivados da 3- (3-hidróxifenil)-3-amino-propionamida | |
DE60303929D1 (de) | Chemokin-muntanten mit verbesserter oraler bioverfügbarkeit | |
BRPI0415428A (pt) | formulações terapêuticas | |
IT1302289B1 (it) | Composizioni farmaceutiche ad attivita' antineoplastica | |
DE60018400D1 (de) | Zusammensetzungen von duftstoffvorstufen und verfahren zum hervorbringen von duftstoffen | |
ATE234320T1 (de) | Beta,beta-disubstituierte derivate von 9-deoxo-9a-n-ethenyl-9a-aza-9a-homoerythromycin a | |
CY1109453T1 (el) | Παραγωγα κινολινης και η χρηση τους στο γλαυκωμα και τη μυωπια | |
ECSP003349A (es) | Derivados de mevinolina | |
ECSP003412A (es) | Derivados de 3- amino -3-arilpropan - 1 - ol, su preparacion y su uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |